Evidence map›Paper›PMID 42519320›Full record

ArticleFrontiers in immunology2026

Case Report: Successful R0 resection following conversion immunochemotherapy in a patient with biliary tract cancer and multiple metastases discovered after laparoscopic gallstone surgery.

Yan Wang, Shulong Zhang, Ningjia Shen, Jiahui Chen, Jinyan Zhao, Chang Xu, Xiaojian Ni, Jiamin Lu, Ying Zhou, Sheng Shen and 5 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yan Wang *Department of General Medicine, Shanghai Xuhui District Central Hospital, Zhongshan-Xuhui Hospital, Fudan University, Shanghai, China.
Shulong Zhang *Department of General Surgery, Shanghai Xuhui District Central Hospital, Zhongshan-Xuhui Hospital, Fudan University, Shanghai, China.
Ningjia Shen *Department of General Surgery, Shanghai Xuhui District Central Hospital, Zhongshan-Xuhui Hospital, Fudan University, Shanghai, China.
Jiahui Chen *Department of General Medicine, Shanghai Xuhui District Central Hospital, Zhongshan-Xuhui Hospital, Fudan University, Shanghai, China.
Jinyan Zhao *Department of General Medicine, Shanghai Xuhui District Central Hospital, Zhongshan-Xuhui Hospital, Fudan University, Shanghai, China.
Chang Xu *Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Xiaojian Ni *Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Jiamin LuDepartment of General Medicine, Shanghai Xuhui District Central Hospital, Zhongshan-Xuhui Hospital, Fudan University, Shanghai, China.
Ying ZhouDepartment of General Medicine, Shanghai Xuhui District Central Hospital, Zhongshan-Xuhui Hospital, Fudan University, Shanghai, China.
Sheng ShenDepartment of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Bin LiDepartment of Pathology, Shanghai Xuhui Central Hospital, Fudan University, Shanghai, China.
Jun ZhouDepartment of Nuclear Medicine, Shanghai Xuhui Central Hospital, Fudan University, Shanghai, China.
Yonghua XuDepartment of Imaging and Interventional Radiology, Shanghai Xuhui Central Hospital, Xuhui Hospital of Fudan University, Shanghai, China.
Yuan JiDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Houbao LiuDepartment of General Surgery, Shanghai Xuhui District Central Hospital, Zhongshan-Xuhui Hospital, Fudan University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gallbladder cancer is usually discovered as an incidental finding during or after cholecystectomy for gallstones. Most patients have advanced gallbladder cancer at diagnosis and have lost the opportunity for radical surgery, leading to dismal prognosis. Standard conversion therapy regimen is still in exploration. We reported a patient with unresectable biliary tract cancer (most likely gallbladder cancer) and multiple metastases (TxN2M1) discovered one month after laparoscopic gallstone surgery. The patient received margin-free resection after 9 cycles of immunotherapy (camrelizumab) combined with chemotherapy, followed by adjuvant immunochemotherapy. Pathological complete response was achieved and no disease recurrence occurred 5 months after surgery. Decreased neutrophil count was the only grade 3-4 treatment-related adverse event during the 9 cycles of conversion therapy. This case provides some reference for the conversion therapy of advanced gallbladder cancer or other biliary tract cancers.

Indexed as

Biliary Tract NeoplasmsGallbladder NeoplasmsGallstonesImmunotherapyAntibodies, Monoclonal, HumanizedCholecystectomy, LaparoscopicCombined Modality TherapyHumansLaparoscopyNeoplasm MetastasisPathologic Complete ResponseTreatment OutcomeAntibodies, Monoclonal, Humanizedcamrelizumabcase reportconversion therapygallbladder cancermargin-free resection

Identifiers

PMID42519320
PMCPMC13382423

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.